Corporate Overview

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life.


Our lead product, EGRIFTA® (tesamorelin for injection), was approved by the U.S. Food and Drug Administration  in November 2010 and is the only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. For more information on EGRIFTA® (tesamorelin for injection), please visit the web site

EGRIFTA™ (tesamorelin for injection) was also approved on April 30, 2014 by Health Canada for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients.